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Haemorrhoidal artery ligation versus rubber band ligation 
for the management of symptomatic second-degree and 
third-degree haemorrhoids (HubBLe): a multicentre, 
open-label, randomised controlled trial
Steven R Brown, James P Tiernan, Angus J M Watson, Katie Biggs, Neil Shephard, Allan J Wailoo, Mike Bradburn, Abualbishr Alshreef, Daniel Hind, 
The HubBLe Study team*
Summary
Background Optimum surgical intervention for low-grade haemorrhoids is unknown. Haemorrhoidal artery ligation 
(HAL) has been proposed as an eﬃ  cacious, safe therapy while rubber band ligation (RBL) is a commonly used 
outpatient treatment. We compared recurrence after HAL versus RBL in patients with grade II–III haemorrhoids.
Methods This multicentre, open-label, parallel group, randomised controlled trial included patients from 17 acute 
UK NHS trusts. We screened patients aged 18 years or older presenting with grade II–III haemorrhoids. We 
excluded patients who had previously received any haemorrhoid surgery, more than one injection treatment for 
haemorrhoids, or more than one RBL procedure within 3 years before recruitment. Eligible patients were randomly 
assigned (in a 1:1 ratio) to either RBL or HAL with Doppler. Randomisation was  computer-generated and stratiﬁ ed 
by centre with blocks of random sizes. Allocation concealment was achieved using a web-based system. The study 
was open-label with no masking of participants, clinicians, or research staﬀ . The primary outcome was recurrence 
at 1 year, derived from the patient’s self-reported assessment in combination with resource use from their general 
practitioner and hospital records. Recurrence was analysed in patients who had undergone one of the interventions 
and been followed up for at least 1 year. This study is registered with the ISRCTN registry, ISRCTN41394716.
Findings From Sept 9, 2012, to May 6, 2014, of 969 patients screened, 185 were randomly assigned to the HAL group and 
187 to the RBL group. Of these participants, 337 had primary outcome data (176 in the RBL group and 161 in the HAL 
group). At 1 year post-procedure, 87 (49%) of 176 patients in the RBL group and 48 (30%) of 161 patients in the HAL 
group had haemorrhoid recurrence (adjusted odds ratio [aOR] 2·23, 95% CI 1·42–3·51; p=0·0005). The main reason 
for this diﬀ erence was the number of extra procedures required to achieve improvement (57 [32%] participants in the 
RBL group and 23 [14%] participants in the HAL group had a subsequent procedure for haemorrhoids). The mean pain 
1 day after procedure was 3·4 (SD 2·8) in the RBL group and 4·6 (2·8) in the HAL group (diﬀ erence –1·2, 95% CI 
–1·8 to –0·5; p=0·0002); at day 7 the scores were 1·6 (2·3) in the RBL group and 3·1 (2·4) in the HAL group (diﬀ erence 
–1·5, –2·0 to –1·0; p<0·0001). Pain scores did not diﬀ er between groups at 21 days and 6 weeks. 15 individuals reported 
serious adverse events requiring hospital admission. One patient in the RBL group had a pre-existing rectal tumour. Of 
the remaining 14 serious adverse events, 12 (7%) were among participants treated with HAL and two (1%) were in those 
treated with RBL. Six patients had pain (one treated with RBL, ﬁ ve treated with HAL), three had bleeding not requiring 
transfusion (one treated with RBL, two treated with HAL), two in the HAL group had urinary retention, two in the HAL 
group had vasovagal upset, and one in the HAL group had possible sepsis (treated with antibiotics). 
Interpretation Although recurrence after HAL was lower than a single RBL, HAL was more painful than RBL. 
The diﬀ erence in recurrence was due to the need for repeat bandings in the RBL group. Patients (and health 
commissioners) might prefer such a course of RBL to the more invasive HAL.
Funding NIHR Health Technology Assessment programme.
Copyright © Brown et al. Open Access article distributed under the terms of CC BY.
Introduction
Haemorrhoids result from enlargement of the 
haemorrhoidal plexus and pathological changes in the 
anal cushions, a normal component of the anal canal. They 
are common, aﬀ ecting about a third of the population.1 
Approximately 23 000 haemorrhoidal operations were 
done in England in 2004–05.2 Repeated visits to hospital 
for therapy represent an important disruption to personal 
and working lives.
Treatment depends on the degree of symptoms and 
prolapse, ranging from dietary advice, outpatient rubber 
band ligation (RBL), to operation requiring anaesthesia. 
Although RBL is cheap and serious complications rare, 
recurrence is common, particularly where prolapse is 
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substantial.3 Patients often require further banding.3 
Although variations exist (eg, ligasure haemorrhoidectomy), 
surgery is usually traditional haemorrhoidectomy or a 
stapled haem orrhoidopexy, both requiring anaesthesia. 
Traditional haemorrhoidectomy is associated with con-
siderable postoperative discomfort, sometimes neces-
sitating admission to hospital and delayed return to normal 
activity, but recurrence is low. Stapled haem orrhoid opexy 
has a slightly higher recurrence rate but patients return to 
normal activity more quickly than with traditional 
haemorrhoidectomy.4
An alternative treatment is haemorrhoidal artery 
ligation (HAL). Although requiring anaesthesia, evidence 
suggests a recovery similar to RBL, but an eﬀ ectiveness 
that approaches the more intensive surgical options. As a 
consequence, the HAL procedure has gained popularity, 
with more than 5000 procedures carried out in the UK 
per year (manufacturer communication).
Estimates of HAL eﬃ  cacy come from several 
randomised trials, four systematic reviews,5–8 and one 
overview by the National Institute for Health and Care 
Excellence (NICE).9 All publications highlight the lack of 
good quality data as evidence for the advantages of the 
technique. To our knowledge, there are no existing 
randomised trials comparing HAL with RBL.
We aimed to establish the clinical and cost-
eﬀ ectiveness of HAL compared with RBL in the 
treatment of symp tomatic second-degree and third-
degree haem orrhoids. The primary objective was 
to compare patient-reported symptom recurrence 
12 months after intervention.
Methods
The protocol was published in 2012;10 protocol 
amendments subsequent to trial commencement are 
provided in the appendix.
Study design and participants
This multicentre, parallel-group randomised controlled 
trial took place in 17 acute UK NHS hospitals. Delegated 
study staﬀ  at these 17 hospitals identiﬁ ed and consented 
potential participants. Eligible participants were aged 
18 years or older with symptomatic second-degree or third-
degree haemorrhoids.11 We excluded patients who had 
previously received any haemorrhoid surgery, more than 
one injection treatment for haemorrhoids, or more than 
one RBL procedure within 3 years before recruitment. We 
also excluded patients with perianal sepsis, inﬂ ammatory 
bowel disease, colorectal malignancy, pre-existing 
sphincter injury, and immuno deﬁ ciency, hypercoagulability 
disorders, and patients who were unable to have general or 
spinal anaesthetic. Sheﬃ  eld CTRU coordinated follow-up 
and data collection in collaboration with these centres. The 
study was approved by the NRES Committee South 
Yorkshire (REC reference 12/YH/0236). All participants 
provided written informed consent.
Randomisation and masking
Participants were individually randomly assigned (in a 
1:1 ratio) to receive either HAL or RBL. Randomisation 
was computer-generated and stratiﬁ ed by centre using 
permuted blocks of random sizes two, four, and six. 
Allocation concealment was achieved using a centralised 
Research in context
Evidence before this study
Haemorrhoidal arter y ligation (HAL) is a relatively new procedure 
that has become increasingly established as a treatment for 
haemorrhoids. A NICE overview in 2010 and four systematic 
reviews published between 2009 and 2015 highlight the lack of 
good quality data as evidence for the advantages of the HAL 
technique. The reviews included ﬁ ve randomised trials, two 
comparative cohort trials, and 21 cohort studies. From these 
reviews, the pooled recurrence rate for HAL ranged from 
11% to 17·5%. A commonly used technique for treatment of early 
grade haemorrhoids is rubber band ligation (RBL). This technique 
is simple and easy to carry out, requiring no anaesthetic and with 
rapid recovery. It is the obvious comparator for treatment of 
early grade haemorrhoids. To date, there have been no 
randomised trials that have compared HAL with RBL.
Added value of this study
We did a multicentre, parallel-group randomised controlled trial 
of 370 patients comparing HAL with RBL. The recurrence rate 
for HAL was signiﬁ cantly lower than for RBL (30% vs 49%, 
p=0·001) at 12 months. Further treatment was required in 31% 
of the RBL group and 15% of the HAL group (adjusted odds ratio 
[aOR] for further procedure 2·86, 95% CI 1·65–4·93; p=0·0002). 
18% of the RBL group required a second banding session within 
the year. Excluding these patients as recurrence if they reported 
improvement or cure at 1 year resulted in a larger reduction of 
our recurrence rate for RBL and no statistical diﬀ erence between 
the groups (HAL 30% vs RBL 37·5%, aOR 1·35, 0·85–2·15; 
p=0·20). Quality of life, symptom severity score, continence 
score, and complications occurred at a similar frequency. Pain 
was greater and lasted longer after an HAL procedure. The 
health-care cost analysis was striking. In the base case results, 
HAL was around £1000 more expensive and is highly unlikely to 
be cost-eﬀ ective at the £20 000–30 000 threshold.
Implications of all the available evidence
The results of this study suggest both procedures have a higher 
recurrence rate than previously reported. Although the recurrence 
rate at 1 year is lower for HAL compared with a single RBL, many 
clinicians would consider RBL as a course of treatment. If those 
with repeat RBL within the year are excluded as recurrence if they 
reported cure or improvement at 1 year, the recurrence rate was 
similar. Other outcomes were also similar or worse (in terms of 
pain) after HAL. HAL is more expensive and not cost-eﬀ ective.
See Online for appendix
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web-based randomisation system in which the participant 
identiﬁ er was entered before the allocation was revealed. 
The study was open-label with no blinding of participants, 
clinicians, or research staﬀ .
Procedures
The pre-randomisation and baseline questionnaires 
included EQ-5D, pain visual analogue scale (VAS), Vaizey 
faecal incontinence score, and the Haemorrhoid 
Symptom Severity (HSS) score. Baseline data collected 
before the procedure (usually on the day of surgery) 
included ethnic origin, smoking history, height, weight, 
comorbidities, grade of haemorrhoid, and previous 
treatments for haemorrhoids.
RBL is performed with a device that applies a rubber 
band to each haemorrhoid via a proctoscope. This band 
constricts the blood supply causing it to become ischaemic 
before being sloughed oﬀ  1–2 weeks later. The resultant 
ﬁ brosis reduces any prolapse that might be present. The 
procedure is a basic surgical skill that all senior staﬀ 
within the NHS are familiar with and competent in 
performing. Bands were applied at the discretion of the 
surgeon but with a view to resolution of all disease.
HAL is performed with a proctoscope modiﬁ ed to 
incorporate a Doppler transducer. There are two types of 
equipment in common use, the HALO device (AMI HAL 
Doppler system, CJ Medical, Truro, UK) and the THD 
device (THD Lab, Correggio, Italy). Both devices enable 
accurate detection and targeted suture ligation of the 
haemorrhoidal arteries. When combined with a so-called 
pexy suture, both bleeding and haemorrhoidal prolapse 
are addressed. All surgeons participating in the trial 
ensured the need for a pexy suture due to prolapse was 
routinely assessed and recorded. The procedure is 
simple, uses existing surgical skills, and has a short 
learning curve, with the manufacturers recommending 
at least ﬁ ve mentored cases before independently 
practising. All surgeons involved in the study had 
completed this training and had carried out an additional 
ﬁ ve independent procedures before recruitment.
Day 1, 7, and 21 questionnaires were given to the 
participants following their procedure and data were 
either collected over the telephone or the questionnaire 
was returned by post or handed in at the 6 week visit. 
These questionnaires included EQ-5D and a pain VAS.
Questionnaires at 6 weeks were collected at the clinic 
visit (or over the telephone if there was no visit); these 
included EQ-5D, pain VAS, Vaizey score, HSS, and 
questions regarding further treatment. 
The clinical assessment form was completed at the 
6 week visit by the consultant or from patient notes. If a 
proctoscopy was completed, this information was 
recorded here, along with a recurrence question (same as 
the primary outcome question) data on any complications, 
further treatment and planned treatment.
To identify the proportion of patients with recurrent 
haemorrhoids at 12 months after intervention, since no 
validated patient-reported symptom score exists, we asked 
participants a question, 12 months post-intervention:12 “At 
the moment, do you feel your symptoms from your 
haemorrhoids are: (1) cured or improved compared with 
before treatment; or (2) unchanged or worse compared 
with before treatment?”
Patients were considered to have recurrent haemorrhoids 
when any of the following were recorded: “unchanged or 
worse compared with before starting treatment” at 
12 months, patient reported; “any subsequent procedure” 
(RBL, HAL, haemorrhoidectomy, haemorrhoidopexy, 
haemorrhoidal injection or other relevant procedure) over 
the 12 months (general practitioner [GP] and/or hospital 
records); or presence of any symptoms or events that 
strongly indicate recurrence (among patients not meeting 
the two previous criteria), as adjudicated by two blinded 
trial investigators (JPT, SRB; appendix).
Other data collected from questionnaires at 12 months 
were: EQ-5D, pain VAS, Vaizey score, HSS, and questions 
regarding further treatment.
Postoperative assessment was included in the protocol, 
but was not carried out universally. If patients said they 
were better, many surgeons did not re-examine. This 
practice is in line with current majority clinical practice.
Complementary, adjunctive treatments (eg, dietary 
counselling, stool hygiene and habits, use of ﬁ bre, use of 
local therapies such as vasoconstrictors) were not 
speciﬁ cally included in the trial and were prescribed at 
surgeon’s discretion along the lines of the pragmatic 
study design.
Outcomes
The primary outcome was the proportion of patients with 
recurrent haemorrhoids at 12 months after procedure, 
derived from the patient’s self-reported assessment in 
combination with resource use from their GP and 
hospital records.
Secondary endpoints assessed at 6 weeks and 
12 months were: symptom severity (assessed with 
an HSS adapted from Nyström and colleagues),13 
incontinence inventories (assessed using the validated 
Vaizey faecal incontinence score),10 pain (assessed using 
a 10 cm VAS), surgical complications, need for further 
treatment, persistent symptoms at 6 weeks, and health-
state utility based on the EQ-5D.10 
Statistical analysis
Assuming the proportion of patients who experience 
recurrence after RBL is 30% and after HAL is 15%, the 
sample size required for 80% power and 5% signiﬁ cance 
was 121 individuals per group. To account for any 
between-surgeon variation and loss to follow-up, this 
number was increased to 175 per group, on the basis of a 
10% attrition and a conservative assumption that there 
would be 14 surgeons in the trial and an intraclass 
correlation (ICC) of 2·5% in keeping with typical ICCs.14 
However, we considered it likely that each site would 
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have at least two surgeons, in which case the power to 
detect this diﬀ erence was 85%; 90% power if there was 
no between-surgeon variation. Because the surgical 
procedure was well developed and standardised, ICC was 
expected to be virtually zero and we expected the 
proposed sample size to have closer to 90% power.
We did the primary analyses in individuals who had 
undergone one of the interventions and been followed 
up for at least 1 year (deﬁ ned as the study population in 
text). We did additional analyses in the per-protocol (PP) 
population, restricted to those individuals who complied 
with the protocol. Deviations from the protocol that were 
not considered in relation to PP analysis were related 
to the consent process, missed windows for the 
assessments, eligibility (two leading to amending the 
exclusion criteria and two ineligible participants were 
withdrawn), and one participant was given general 
anaesthetic for the RBL procedure. 
We did the analysis of recurrence using a random 
intercept logistic regression model in which covariates 
were treatment allocation, sex, age at surgery, and history 
of previous intervention as ﬁ xed eﬀ ects; the surgeon was 
included as a random eﬀ ect. Further sensitivity analyses 
assessed whether other baseline characteristics (symptom 
score, EQ-5D-5L, body-mass index) altered the strength or 
appeared to modify the treatment eﬀ ect. We compared the 
severity of haemorrhoidal symptoms between groups 
using a generalised least squares regression model, with 
the same covariates as the primary outcome. We did some 
sensitivity analyses that adjusted for severity at 
randomisation (where available), at baseline, and the 
average of the two. The diﬀ erence in symptom severity was 
compared separately for the 6-week and 12-month 
timepoints. We analysed EQ-5D-5L, incontinence, and 
pain in the same manner as symptoms. We compared 
descriptively the secondary outcome of complications 
elicited during the complications review interview or from 
the patient notes at 6 weeks and 1 year after intervention. A 
planned analysis of the time to recurrence was dropped 
because of the diﬃ  culty of eliciting the time of patient-
reported recurrence.
All conﬁ dence intervals were two-sided 95% intervals 
comparing HAL to RBL and all statistical hypotheses 
were two-sided tests. We did a cost-utility analysis in 
terms of incremental cost per quality-adjusted life-years 
(QALYs) gained. We calculated the costs (including 
repeat procedures) following the standard three stage 
approach: identiﬁ cation of resource use, measurement, 
and valuation using the National NHS reference costs. 
We did a secondary cost-eﬀ ectiveness analysis, which 
estimated incremental cost per recurrence avoided. All 
costs were estimated from the NHS and personal social 
perspective as per NICE recommendations.15 Analyses 
were undertaken using the R and Stata programs.  
This project will be published in full in the Public 
Health Research journal series. This trial is registered 
(ISRCTN41394716).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Sept 9, 2012, and May 6, 2014, 372 participants 
(of the 969 screened) were randomly assigned to receive 
RBL or HAL; 187 participants were allocated to receive 
RBL, and 185 were allocated to receive HAL (ﬁ gure 1). 
Figure 1: Trial proﬁ le
RBL=rubber band ligation. HAL=haemorrhoidal artery ligation.
773 eligible patients
969 patients screened 
187 randomised to RBL 185 randomised to HAL 
 158 received  HAL
 3 switched to RBL
196 did not meet eligibility criteria 
1 withdrew as ineligible
 86 completed pre-randomisation questionnaire
 182 completed baseline clinical assessment
 149 completed baseline questionnaire
 162 completed day 1 questionnaire
 157 completed day 7 questionnaire 
 151 completed day 21 questionnaire
 141 completed day 1 questionnaire
 133 completed day 7 questionnaire 
 129 completed day 21 questionnaire
 150 completed 6-week clinical assessment
 144 completed 6-week questionnaire
 143 completed 6-week clinical assessment
 137 completed 6-week questionnaire
7 withdrew before procedure 
2 withdrew consent
1 withdrew as ineligible 
 89 completed pre-randomisation questionnaire 
 166 completed baseline clinical assessment
 152 completed baseline questionnaire
 4 withdrew after procedure 
 46 patient data not obtained
 176 included in primary analysis 
 176 completed 12-month consultant form
 131 completed 12-month participant questionnaire
 122 completed 12-month GP form
36 patient data not obtained
 161 included in primary analysis
 161 completed 12-month consultant form
 125 completed 12-month participant questionnaire
 114 completed 12-month GP form
24 withdrew before procedure 
372 patients randomised 
401 did not consent
 175 received  RBL  
 4 switched to HAL
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Two of these participants (both randomly assigned to 
RBL) were removed from the trial completely due to 
ineligibility: one before the procedure, and the second 
after the procedure. Of the 370 randomised participants 
who were followed up, 340 received treatment (ﬁ gure 1); 
their baseline characteristics are shown in table 1.
340 participants received treatment (ﬁ gure 1). Primary 
outcome data were available for 337 participants (161 in 
the HAL group and 176 in the RBL group). At 12 months, 
256 fully completed patient questionnaires, 236 GP forms, 
and 337 consultant forms were returned. Follow-up was 
completed at sites on Aug 28, 2015. The median time from 
surgery to follow-up was 367 days (365–385) for the RBL 
group and 367 days (365–374) for the HAL group. There 
were 183 participants for whom all three of the 12 months 
forms were fully completed and returned (98 in the RBL 
group and 88 in the HAL group). The analysis population 
included all 176 participants in the RBL group and 
161 participants in the HAL group for whom recurrence 
data were available, from either the patient, clinician, or 
GP. Four participants received HAL despite being 
randomly assigned to RBL, whereas three participants 
assigned to HAL received RBL. Since the ﬁ ndings in the 
primary analysis population and the PP population were 
similar, the reporting is restricted to the primary analysis 
population, with the exception of adverse events and 
complications which are by treatment received.
The number of participants with a recurrence at 
12 months was 87 (49%) in the RBL group compared with 
48 (30%) in the HAL group (adjusted odds ratio [aOR] 2·23, 
95% CI 1·42–3·51, ICC=0·000; p=0·0005). The breakdown 
of recurrences, overall and by criteria is presented in 
table 2. The proportion of participants who reported 
recurrence was similar between groups, with 29% of 
respondents in both groups stating they believed symptoms 
from their haemorrhoids were unchanged or worse (aOR 
for self-reported recurrence 1·06, 0·60–1·85; p=0·85). The 
increased recurrence associated with RBL was mainly 
attributable to the high rate of additional procedures 
undertaken following initial intervention (32%), compared 
with 14% in the HAL group by 1 year follow-up (aOR for 
further procedure 2·86, 1·65–4·93; p=0·0002). A further 
three (2%) participants in the RBL group were considered 
to have symptoms consistent with recurrent haemorrhoids 
following review of medical contacts and procedures over 
the 12 month follow-up, which were undertaken blind to 
treatment group: in two cases the participants were 
recorded as possibly requiring further treatment at their 
6-week visit but were subsequently lost to follow-up; a third 
had been admitted to hospital twice for excessive bleeding 
but had not undergone treatment.
At 6 weeks, data were available for 293 patients (ﬁ gure). 
43 (29%) of 150 participants in the RBL group reported 
their haemorrhoids as unchanged or worse, compared 
with 12 (8%) of 143 participants in the HAL group; 
additionally, one participant in each group had subsequently 
undergone RBL. Thus the overall number of patients with 
persistent symptoms was 44 (29%) versus 13 (9%); adjusted 
odds ratio 4·35 (95% CI 2·19–8·65; p<0·0001).
At 6 weeks, HSS scores were higher in the RBL group, 
indicating short-term symptoms were less pronounced 
following HAL (appendix). The mean scores were 4·0 
(SD 3·5) in the RBL group and 3·0 (3·1) in the HAL 
group, with an adjusted diﬀ erence in means of 1·0 
(95% CI 0·3 to 1·8; p=0·010). No diﬀ erence was apparent 
at 12 months, with the mean being 3·6 (3·2) for RBL and 
3·6 (3·3) for HAL (adjusted diﬀ erence 0·0, 95% CI 
–0·8 to 0·8; p=0·98).
RBL (n=176) HAL (n=161)
Sex
Male 99 (56%) 85 (53%)
Female 77 (44%) 76 (47%)
Age, years
Mean (SD) 49·0 (12·9) 48·5 (13·5)
Median (IQR) 50·5 (38·5–58·0) 49·0 (38·0–60·0)
Range 21·9–79·3 20·2–74·6
Body-mass index, kg/m²
Mean (SD) 28·0 (557) 28·2 (7·1) 
Median (IQR) 27·0 (24·4–31·7) 26·8 (24·1–30·0)
Range 17·4–44·9 18·8–67·4
Grade of haemorrhoids
II (%) 115 (65%) 92 (57%)
III (%) 60 (34%) 68 (42%)
Missing 1 (0·6%) 1 (0·6%)
Previous treatment
No (%) 124 (70%) 124 (70%)
Yes (%) 52 (30%) 36 (22%)
Missing 0 1 (0·6%)
Procedure information
Number of patients receiving procedure 172 (98%) 158 (98%)
Median time from randomisation to procedure, days (IQR) 0 (0–19) 62 (39–91)
Number of patients receiving treatment on the same day 
as randomisation
114 (63%) 0
Data are n (%) or median (IQR). RBL=rubber band ligation. HAL=haemorrhoidal artery ligation. 
Table 1: Baseline demographic data by randomised group
RBL (n=176) HAL (n=161)
Recurrence 87 (49%) 48 (30%)
Criteria for recurrence*
Self-reported recurrence 37/130 (29%†) 34/124 (29%†)
Subsequent procedure for haemorrhoids 57 (32%) 23 (14%)
RBL 31 (18%) 14 (9%)
HAL 23 (13%) 7 (4%)
Excisional haemorrhoidectomy 4 (2%) 7 (4%)
Stapled haemorrhoidopexy 2 (1%) 1 (1%)
Residual untreated symptoms from blinded review 3 (2%) 0
RBL=rubber band ligation. HAL=haemorrhoidal artery ligation. *More than one criterion may apply. †Denominator is 
the number of patients returning the questionnaire (or form). 
Table  2: Recurrence at 12 months after procedure 
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Before intervention, the mean health utility (EQ-5D-5L) 
was around 0·9 in both groups but declined at days 1 and 7 
in the HAL group (ﬁ gure 2). For RBL the mean at day 1 was 
0·84 (SD 0·19) and at day 7 it was 0·92 (0·15); in other 
words, health state was reduced for the ﬁ rst day but had 
reverted back at 1 week. By contrast, the mean health state 
for HAL had not returned to baseline values by day 7, with 
the mean being 0·76 (0·22) at day 1 and 0·83 (0·18) at day 7. 
The adjusted diﬀ erence in means were 0·08 (95% CI 
0·04–0·13; p<0·001) at day 1 and 0·08 (0·05–0·12; p=0·001) 
at day 7. The mean health utility was nearly similar with no 
statistical diﬀ erences between the two groups (and above 
baseline values) at all timepoints from day 21 onwards.
The Vaizey faecal incontinence score was similar 
between groups (appendix). An improvement of around 
one unit was noted in both groups at 6 weeks, with a 
diﬀ erence between groups of –0·1 (95% CI –1·3 to 1·0; 
p=0·86). The improvement was maintained at 1 year, 
with a diﬀ erence of 0·5 (95% CI –0·7 to –1·8; p=0·38).
Patients rated their current pain due to haemorrhoids at 
baseline and at four timepoints over the subsequent 6 weeks 
using a 10-point VAS. HAL was associated with more short-
term pain than was RBL. The mean pain 1 day after 
procedure was 3·4 (SD 2·8) in the RBL group and 4·6 (2·8) 
in the HAL group (diﬀ erence –1·2, 95% CI –1·8 to –0·5; 
p=0·0002); at day 7 the mean scores were 1·6 (2·3) in the 
RBL group and 3·1 (2·4) in the HAL group (diﬀ erence –1·5, 
–2·0 to –1·0; p<0·0001). The mean pain was similar 
between groups at 21 days (1·3 [2·0] in the RBL group vs 1·4 
[1·9] in the HAL group; diﬀ erence –0·1, –0·6 to 0·3; p=0·44) 
and 6 weeks (1·2 [2·1] in the RBL group vs 1·0 [1·8] in the 
HAL group; diﬀ erence 0·2, –0·2 to 0·7; p=0·32).
15 individuals reported serious adverse events requiring 
hospital admission (table 3). One patient experienced 
several episodes of bleeding after RBL; further investigations 
revealed a rectal tumour. This serious adverse event was 
classiﬁ ed as pre-existing and was not included. Of the 
remaining 14 serious adverse events, 12 (7%) were among 
participants treated with HAL (one of whom had been 
switched from the RBL group) and two (1%) were in those 
treated with RBL. Six patients had pain requiring prolonged 
hospital stay (ﬁ ve treated with HAL, one treated with RBL), 
three had bleeding (not requiring transfusion, two treated 
with HAL, one treated with RBL), two had urinary retention, 
two had vasovagal upset, and one had possible sepsis 
(treated with antibiotics); all 14 events were prespeciﬁ ed as 
expected in the study protocol.
The main ﬁ ndings of within trial cost-utility analysis 
suggest that the HAL procedure appeared not to be cost-
eﬀ ective compared with RBL at a cost-eﬀ ectiveness 
threshold of £20 000–30 000 per QALY. In the base-case 
results, the diﬀ erence in mean total costs was £1027 
higher for HAL than for RBL (table 4). QALYs were 
higher for HAL than for RBL; however, the diﬀ erence 
was very small (0·010), resulting in an incremental cost-
eﬀ ectiveness ratio (ICER) of £104 427 per additional 
QALY. At £20 000 per QALY threshold, HAL has zero 
probability of being cost-eﬀ ective; at £30 000 threshold, it 
has 0·05 probability of being cost-eﬀ ective.
The mean total cost per patient for HAL was £1750 
(95% CI 1333–2167) compared with £723 (551–896) for 
RBL (table 3). 
Among the 80 participants who required a further 
procedure, the majority (15 of 23 in the HAL group and 
45 of 57 in the RBL group) underwent a single procedure 
and in most cases this was RBL, although some variation 
was noted across centres: the cost of an additional RBL 
procedure in this trial was £523·16. As RBL is a brief 
outpatient procedure with (relatively) minimal 
inconvenience to the patient, it could be argued that a 
repeat RBL is not itself indicative of a recurrence. 
Figure 2: Mean EQ-5D scores with 95% CIs over 12 months follow-up
Some participants did not complete all measures in the forms, ﬁ ve participants (three in the RBL group, two in the 
HAL group) did not complete the EQ-5D score measure. RBL=rubber band ligation. HAL=haemorrhoidal artery 
ligation.
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Table 4: The mean diﬀ erence in total costs and QALYs for HAL versus RBL 
RBL group 
(n=178)
HAL group 
(n=162)
Any serious adverse events 2 (1%) 12 (7%)
Excessive bleeding 0 3 (2%)
Urinary retention 0 2 (1%)
Sepsis 0 1 (<1%)
Pain requiring hospital admission 1 5*
Vasovagal upset 1 1
RBL=rubber band ligation. HAL=haemorrhoidal artery ligation. *Includes one 
patient randomly assigned to RBL, but who received HAL.
Table 3: Serious adverse events
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Consequently, we did an additional post-hoc analysis to 
investigate the extent to which recurrence diﬀ ered 
between an outpatient course of RBL treatment and HAL 
(ie, excluding second bandings in the RBL group). Of the 
31 patients in the RBL group who underwent repeat RBL, 
21 were reclassiﬁ ed as non-recurrences since they 
reported being cured or improved at 1 year. This analysis 
changed the number of recurrences to 66 (37·5%) in the 
RBL group, and 48 (30%) in the HAL group (adjusted 
odds ratio 1·35, 95% CI 0·85–2·15; p=0·20).
A further (post-hoc) analysis looked at the proportion of 
participants whose symptom score was either zero or one, 
since this number corresponds to the deﬁ nition of cure 
used by Nyström.13 The proportions suggest that although 
there were more “cured” patients in the HAL group at 
6 weeks (31% RBL vs 38% HAL) and 1 year (27% RBL vs 
31% HAL), there was no statistical diﬀ erence between the 
groups (adjusted OR 0·73, 0·44–1·22; p=0·23 at 6 weeks 
and OR 0·79, 0·46 to 1·38; p=0·42 at 1 year).
The trial design meant that there was a diﬀ erence 
between interventions in terms of dates of randomisation 
and surgery (RBL was often carried out immediately 
whereas HAL patients went onto a waiting list; see 
table 1). Because of this, baseline data were recorded both 
at randomisation and at the time of surgery. The extent of 
agreement was generally similar regardless of the severity.
Discussion
Recurrence 12 months after HAL was signiﬁ cantly lower 
than after RBL. Haemorrhoidal disease is a benign 
condition with treatment primarily aimed at addressing 
symptoms. In the absence of a validated symptom scoring 
system, we felt the most important determinant of 
treatment success was patient-reported outcome of 
improvement and the need to avoid additional procedures. 
Where patients had undergone further intervention for 
haemorrhoids, they were considered to have recurred. 
Based on this premise, HAL appears superior. This 
apparent superiority should be put in practical context. 
18% of the participants in the RBL group underwent 
repeat banding. This is common practice and patients 
might ﬁ nd this re-banding a more palatable option than 
having an operation if it has the same potential for 
improvement. Indeed some clinicians deem RBL as a 
course of treatment. Including these patients as a success 
(if they reported improvement at 12 months) resulted in a 
reduction in recurrence and no statistical diﬀ erence 
between the groups.
The choice of patient-deﬁ ned recurrence as our primary 
outcome was supported by a robust patient and public 
involvement exercise carried out during trial design. 
Clinical experience indicates that the physical appearance 
of the anal cushions post-treatment correlates poorly with 
patients’ symptoms, meaning anorectal visualisation is 
not a reliable surrogate of success.16 We therefore asked 
participants a question, 12 months after intervention, 
based on a simple, dichotomised deﬁ nition of recurrence 
as described by Shanmugam and colleagues.12 This 
deﬁ nition is not universal—indeed no standardised 
deﬁ nition of recurrence exists. This is the most obvious 
explanation for our recurrence rates following HAL, 
higher than those reported in systematic reviews 
(11–17·5%).5,6 Some previous studies have relied on clinical 
examination and patient-reported symptoms,17–21 others 
solely on symptomatology.22,23 When considering 
symptoms only, some investigators consider a patient 
recurrence-free if they have no perianal symptoms at all; 
others simply an improvement. An example of variation 
dependent on this deﬁ nition is provided by one study 
reporting a recurrence rate of 60%, 30 months after a HAL 
procedure, yet 86% of patients simultaneously described a 
signiﬁ cant improvement in symptoms.22 Other factors 
that inﬂ uence recurrence include duration of follow-up. 
We chose to assess recurrence at 12 months because 
published data suggest most recurrences occur in less 
than 1 year.19 However, our data indicate that persistent 
symptoms were lower for both groups at 6 weeks (HAL 
9% vs RBL 29%) with major deterioration over the year 
and it is not clear if or when this deterioration plateaus.
The mean symptom severity score improved after both 
interventions by 2 to 3 points on a 15 point scale at 6 weeks. 
Accounting for other variables in the model (age, gender, 
previous treatment, and baseline score), those undergoing 
RBL had a higher HSS score at this timepoint but no 
diﬀ erence was apparent at 1 year. The improvement after 
both interventions was not as great as that seen by Nyström 
and colleagues who observed a diﬀ erence of about 6 points 
after intervention.12 However, in that study the preoperative 
score was higher than in ours, reﬂ ecting a higher grade of 
haemorrhoids pre-treatment.
Applying the Nyström deﬁ nition of cure as 0–1 point on 
this scoring system,13 there was no diﬀ erence between the 
two interventions at any timepoint. Indeed, it is striking 
how few patients reported such a score despite considering 
themselves to be cured or improved according to our 
primary outcome measure. This ﬁ nding suggests that 
many patients are not concerned with a certain level of 
persistent symptoms related to haemorrhoids.
Intervention for haemorrhoids is essentially aimed at 
improving quality of life, which therefore becomes an 
important indicator of success. Our results suggest that 
the majority of patients in both groups had an 
improvement in quality of life above baseline after 
intervention from day 21 onwards. Before this date there 
was a diﬀ erence in favour of RBL, probably related to the 
fact that the HAL procedure was more painful and pain 
lasted longer. Although no long-term diﬀ erence was seen 
between the two groups, both interventions did result in a 
small improvement in quality-of-life score. Therefore, 
both interventions appear worthwhile from this 
perspective. The alternative management option of 
reassurance following exclusion of a sinister cause for the 
symptoms and giving general lifestyle advice might not be 
appropriate.24
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Resting anal sphincter tone maintains continence and 
the haemorrhoidal tissue contributes to the formation of 
a hermetic seal. It follows that disruption of this tissue 
due to prolapse potentially leads to anal leakage. Our 
results are consistent with this: at baseline the majority 
of participants from both groups had no or very mild 
incontinence. Correction of the prolapse resulted in a 
small reduction in the mean continence score after both 
interventions with no diﬀ erence between interventions.
Most patients reported pain following both procedures. 
For RBL this was usually of low intensity, and resolved 
rapidly to below baseline with approximately half of 
patients requiring analgesics for a few days. For HAL, the 
pain was signiﬁ cantly greater up to 1 week but had 
resolved in almost all patients by 3 weeks. Daily analgesia 
was required by most for the ﬁ rst week but tailed oﬀ , such 
that at 3 weeks three-quarters of patients had stopped 
taking medication. There are few randomised trials where 
VAS scores have been used as we have used them; 
summarising these ﬁ ndings suggests most patients have 
moderate pain in the ﬁ rst few days after an HAL, but that 
this pain recedes to minimal or no pain by 1–3 weeks,22,23,25 
consistent with our results.
The incidence of adverse events was low for both 
treatment groups. Two patients from the RBL group 
required hospitalisation. This is relevant as the procedure 
is usually carried out in the outpatient department, often 
with minimal consent. There is a vogue for some 
hospitals to arrange for the RBL procedure to be carried 
out in a day-case theatre environment, allowing a formal 
consent process. Day-case admission, with a short period 
of observation, may have avoided the need for hospital 
admission in only one patient in our trial who had 
immediate severe pain post-procedure.
The health-care cost analysis is striking. In the base case 
analysis, HAL is around £1000 more expensive than RBL. 
Since there is little diﬀ erence in overall health-related 
quality of life between the two procedures, the ICER per 
additional QALY is very high and signiﬁ cantly exceeds a 
cost-eﬀ ectiveness threshold of £20 000–30 000 per QALY. 
Even if a diﬀ erence in recurrence is assumed (ie, single 
RBL procedure vs HAL) the cost-eﬀ ectiveness ratio in 
terms of cost per recurrence avoided is approximately 
£5000. Essentially, HAL is highly unlikely to be cost-
eﬀ ective at the £20 000–30 000 per QALY threshold.
Data regarding health-care costs from other studies is 
sparse. Cost analysis has been carried out in one trial 
comparing stapled haemorrhoidopexy with RBL,26 with 
the cost of stapled haemorrhoidopexy being substantially 
higher and unlikely to be considered cost-eﬀ ective at 
1 year. However, the authors assumed that the cost due to 
increased recurrence with RBL would mean that this 
diﬀ erence would fall over time. This assumption might 
be true for HAL, although the relative low cost of RBL 
makes it unlikely. It is probably more cost-eﬀ ective for 
patients to return for a further RBL if recurrence occurs 
at any time.
We noted more patients who withdrew in the HAL 
group than in the RBL group. The main reason for the 
diﬀ erence in withdrawal relates to patients withdrawing 
consent. 15 patients from the HAL group withdrew 
consent compared with two from the RBL group. This 
diﬀ erence inevitably relates to the waiting time for 
intervention. RBL was often carried out immediately after 
randomisation whereas for HAL patients were put on a 
waiting list. In some instances the waiting list was very 
long (up to 270 days). There were otherwise no diﬀ erences 
in the baseline characteristics for those that withdrew.
The pragmatic, multicentre design, using a mix of 
NHS district general and teaching hospitals across the 
UK, ensures that the results are generalisable to all 
patients seeking treatment for grade II–III haemorrhoids. 
However, there are potential limitations. First, the length 
of follow-up might not be adequate; extended follow-up 
might demonstrate further deterioration in symptoms, 
altering health-care costs. Second, we used the Goligher 
grading system for haemorrhoids, which has been 
criticised for its deﬁ nition of grade IV haemorrhoids;16 
there is less ambiguity with regard to lower grades but 
misclassiﬁ cation is common.27 Third, although HAL 
appears simple and easy to learn, there might be a 
prolonged learning curve. Some studies describe a 
poorer outcome in initial patients.28,29 Our trial required 
that surgeons had to have carried out at least ﬁ ve 
mentored cases and an additional ﬁ ve procedures before 
recruitment (based on manufacturer recommendations), 
but no data exist to deﬁ ne when competence is reached. 
The ﬁ nal limitation is the lack of a validated scoring 
system for haemorrhoids. At the time of design of this 
trial there were no such systems available. Subsequent to 
our study starting, a scoring system has been developed.30
In conclusion, HAL is more eﬀ ective than single RBL. 
If, however, RBL is considered a course of treatment 
involving repeat banding, the procedures are equally 
eﬀ ective. Similarly, symptom severity score, complications, 
quality of life, and continence score are no diﬀ erent 
between HAL and RBL, and patients had more pain in the 
early postoperative period after HAL. HAL is signiﬁ cantly 
more expensive and unlikely to be cost-eﬀ ective. Because 
of this, patients (and commissioners) might prefer a 
course of RBL for the treatment of haemorrhoids.
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